Sells medicines for people with hypercortisolism and develops cortisol-modulating treatments for patients with cancer and other serious disorders.
10-K for FY2025, filed Feb 24, 2026We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic…View ↗
Since 2012, we have marketed Korlym in the United States for the treatment of patients suffering from hypercortisolism (also known as…View ↗
Our lead compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders – hypercortisolism…View ↗
Corcept sells its medicines to patients through specialty pharmacy vendors and to a specialty distributor. It gets paid when products are delivered; patients need insurance or third-party charity coverage before a sale.
10-K for FY2025, filed Feb 24, 2026We sell our Products directly to patients through specialty pharmacy vendors. We also sell our Products to a specialty distributor (“SD”)…View ↗
To determine our revenue from the sale of our Products, we (i) identify our contract with each customer; (ii) identify the obligations of…View ↗
Confirmation of coverage by private or government insurance or by a third-party charity is a prerequisite for selling our Products to a…View ↗
$761.4M
10-K for FY2025, filed Feb 24, 2026
$761.4M ↗
Patients receive Corcept’s medicines through specialty pharmacy vendors, while a specialty distributor also buys the products. Sales representatives call on physicians who treat hypercortisolism.
10-K for FY2025, filed Feb 24, 2026
Yes. It kept 13 cents of every revenue dollar as net income in FY2025 and turned 19 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 3, 2026
$126.8MView ↗
8-K, filed Jul 29, 2026
Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $208.6…View ↗
8-K, filed Mar 25, 2026
On March 25, 2026, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has…View ↗
Growing. Revenue grew 2.1x in 4 years, from $366M in FY2021 to $761.4M in FY2025, about 20% a year.
Added an authorized generic
The older report described Korlym as the marketed medicine; the latest report also says an authorized generic version is available and sold.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 24, 2026Since 2012, we have marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushing’s syndrome.…View ↗
Broadened cancer research
The older report described work in ovarian, adrenal and prostate cancers; the latest report also lists endometrial, cervical and pancreatic cancers among the targets.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 24, 2026There is substantial evidence that cortisol activity at the GR reduces the efficacy of certain anti-cancer therapies and that modulating…View ↗
Our lead compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders – hypercortisolism…View ↗
Competes with Recordati, Xeris Biopharma Holdings, and Teva Pharmaceuticals USA
10-K for FY2025, filed Feb 24, 2026Our Products compete with established treatments, including surgery, radiation and other medications approved by the FDA for the treatment…View ↗
Loading...